BioXcel Therapeutics Inc (FRA:BX2)
€ 1.892 0.006 (0.32%) Market Cap: 72.49 Mil Enterprise Value: 98.09 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 21/100

BioXcel Therapeutics Inc at Bank of America Biotech SMID Cap Conference Transcript

Dec 07, 2022 / 06:45PM GMT
Release Date Price: €17.25 (-1.51%)
Unidentified Participant

Ladies and gentlemen, the program is about to begin. Reminder that you can submit questions at any time via the ask questions tab on the webcast page. At this time, it is my pleasure to turn the program over to your host, Greg Harrison. You may begin.

Gregory Allen Harrison
BofA Securities, Research Division - Analyst

Hi and welcome to the Bank of America SMID Biotech Virtual Conference. I'm Greg Harrison, one of the biotech analysts here at BofA. And today, I'm happy to introduce BioXcel Therapeutics, represented by Vimal Mehta, CEO; Matt Wiley, Chief Commercial Officer; and Rob Risinger, Chief Medical Officer.

Thanks for joining us, everybody. And for those of you out there watching, if you want to send you questions, I'm happy to ask on your behalf. Vimal, would you like to start off with some opening remarks, and then we can jump into Q&A.

Vimal D. Mehta
BioXcel Therapeutics, Inc. - Founder, CEO, President, & Director

Thanks, Greg. Good afternoon, everyone. I'm Vimal Mehta,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot